

SUPPLEMENTAL DIGITAL CONTENT 5 – TABLE S3

Supplemental digital content: Table S3: MenC-specific serum bactericidal antibody (SBA) geometric mean titres (GMT): Composite 6 and 9-month post-booster data, by primary and booster vaccine, and across all study groups

Booster vaccine	Primary vaccine	n	GMT (95 %CI)
All	<i>Menjugate</i>	33	1433 (777-2642)
	<i>Meningitec</i>	25	1024 (511-2054)
	<i>NeisVac-C</i>	33	2927 (2077-4124)
GSK	All	46	1138 (706-1834)
Novartis	All	45	2541 (1696-3806)
MenACWY-TT	<i>Menjugate</i>	17	983 (413-2342)
	<i>Meningitec</i>	14	538 (189-1532)
	<i>NeisVac-C</i>	15	2702 (1757-4156)
MenACWY-CRM	<i>Menjugate</i>	16	2139 (853-5363)
	<i>Meningitec</i>	11	2323 (1102-4896)
	<i>NeisVac-C</i>	18	3128 (1793-5456)